Resources

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS I.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS VI.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for hereditary tyrosinaemia (type 1).

This departmental review looked at the effectiveness of the National Prescribing Service, NPS MedicineWise, in delivering the Quality Use of Medicines Program.

The Form of the Electronic Prescription 2019 defines the information fields required when a PBS prescriber writes an electronic prescription.

The Electronic Prescriptions Information Technology Requirements Instrument 2019 details system requirements for participating in electronic prescribing and refers to system obligations to adhere to security, privacy and data usage policies.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria.

This final protocol describes the methodology reviewers will follow to assess use of enzyme replacement medicines under the Life Saving Drugs Program medicines for Gaucher disease (type 1).

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Fabry disease.

This document provides a list of PBS medicines often prescribed, including form and strength, as well as PBS codes, for Community Service Obligation (CSO) for Pharmaceutical Wholesalers funding pool stakeholders for 2018–19.